{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"41"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"59"}],"units":"Participants"}],"description":"Complete Response (CR) + Partial Response (PR) + Stable disease","groups":[{"description":"Patients receive docetaxel IV over 1 hour and cisplatin IV over 2 hours or carboplatin IV over 2 hours on day 1 and erlotinib hydrochloride PO daily on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression and unacceptable toxicity. Patients achieving complete response, partial response, or stable disease may continue erlotinib hydrochloride treatment.","id":"OG000","title":"Arm A (Combination Chemotherapy and Erlotinib Hydrochloride)"},{"description":"Patients receive docetaxel and cisplatin or carboplatin as in Arm I and placebo PO daily on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression and unacceptable toxicity. Patients achieving complete response, partial response, or stable disease may continue placebo treatment.","id":"OG001","title":"Arm B (Combination Chemotherapy and Placebo)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"5 years","title":"Disease Control (CR + PR + Stable Disease [SD])","type":"SECONDARY","unitOfMeasure":"Participants"}